Recent News

• 08.25.2025 - LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
• 07.31.2025 - LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
• 07.30.2025 - LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
• 07.28.2025 - LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia
• 07.07.2025 - LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

Recent Filings

• 08.20.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.31.2025 - EX-99.1 EX-99.1
• 07.31.2025 - 8-K Current report
• 07.30.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.30.2025 - EX-99.1 EX-99.1
• 07.30.2025 - 8-K Current report
• 07.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.14.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 07.01.2025 - 4 Statement of changes in beneficial ownership of securities